Literature DB >> 10025809

Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance?

A Papadimitriou1, V Veletza, G M Hadjigeorgiou, A Patrikiou, M Hirano, I Anastasopoulos.   

Abstract

The G209A mutation in the alpha-synuclein gene has been associated with autosomal dominant PD (ADPD) in a family from Contursi, Italy, and three apparently unrelated Greek families. Several groups around the world failed to identify the G209A mutation in a sizable series of familial and sporadic cases of PD. The authors present two additional Greek families with ADPD associated with the G209A mutation. In both families, asymptomatic carriers older than the expected age at onset were found.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025809     DOI: 10.1212/wnl.52.3.651

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease.

Authors:  S Papapetropoulos; C Paschalis; A Athanassiadou; A Papadimitriou; J Ellul; M H Polymeropoulos; T Papapetropoulos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

2.  Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.

Authors:  L Stefanis; K E Larsen; H J Rideout; D Sulzer; L A Greene
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

3.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

Review 4.  Rare genetic mutations shed light on the pathogenesis of Parkinson disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 5.  The heterozygous A53T mutation in the alpha-synuclein gene in a Chinese Han patient with Parkinson disease: case report and literature review.

Authors:  Wei-Xi Xiong; Yi-Min Sun; Rong-Yuan Guan; Su-Shan Luo; Chen Chen; Yu An; Jian Wang; Jian-Jun Wu
Journal:  J Neurol       Date:  2016-07-08       Impact factor: 4.849

6.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

Authors:  K A Conway; S J Lee; J C Rochet; T T Ding; R E Williamson; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

7.  A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction.

Authors:  Andreas Puschmann; Owen A Ross; Carles Vilariño-Güell; Sarah J Lincoln; Jennifer M Kachergus; Stephanie A Cobb; Suzanne G Lindquist; Jørgen E Nielsen; Zbigniew K Wszolek; Matthew Farrer; Håkan Widner; Danielle van Westen; Douglas Hägerström; Katerina Markopoulou; Bruce A Chase; Karin Nilsson; Jan Reimer; Christer Nilsson
Journal:  Parkinsonism Relat Disord       Date:  2009-07-25       Impact factor: 4.891

8.  Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  Neurotox Res       Date:  2011-07-07       Impact factor: 3.911

Review 9.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

Review 10.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.